Company news

Ocugen, Inc. news in 2020

Ocugen, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Ocugen Establishes Vaccine Scientific Advisory Board

December 22, 2020

Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares

December 21, 2020

Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders

December 9, 2020

Ocugen Provides Business Update and Third Quarter 2020 Financial Results

November 5, 2020

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

October 5, 2020

Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

September 7, 2020

Ocugen Provides Business Update and Second Quarter 2020 Financial Results

August 13, 2020

Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

August 9, 2020

Ocugen to Host Conference Call on Friday, August 14 at 8: 30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

August 5, 2020

Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

July 26, 2020

Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

June 2, 2020

Ocugen to Discontinue Phase 3 oGVHD Trial

May 31, 2020

Ocugen Provides Business Update and First Quarter 2020 Financial Results

May 7, 2020

Ocugen Announces Completion of Warrant Exchange

April 21, 2020

Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors

April 6, 2020

Ocugen Provides Business Update and Full Year 2019 Financial Results

March 26, 2020

Decks in 2020